Tag Archives: Affordable Care Act

Business Roundtable: The Reimbursement Landscape under ACA

Capture

As the Affordable Care Act is implemented, reimbursement for life-saving and life-enhancing drugs is one of the most pressing issues facing healthcare stakeholders and decision makers, including patients, payers, providers, and innovative drug developers. BIO hosted a business roundtable discussion on this timely topic yesterday at our 16th Annual BIO CEO & Investor Conference. Moderated by Real Endpoint’s Roger Longman, panelists represented a variety of perspectives: Peter Bach, MD, MAPP, Attending Physician, Memorial Sloan-Kettering Cancer Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Cancer Insurance Checklist: Guía de Cobertura Médica para Personas con Cáncer

20070112

As the world marks World Cancer Day and the U.S. continues to implement the Affordable Care Act, the Cancer Support Community (CSC) is pleased to announce the launch of a Spanish language version of the successful resource, the Cancer Insurance Checklist. This easy-to-use guide is available to assist people with cancer, a history of cancer or at risk for cancer choose a health insurance plan. The need is great.  Nearly a third (31.1 percent) of Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

The Affordable Care Act is Here to Stay

The Affordable Care Act is Here to Stay

The Patient Protection and Affordable Care Act (ACA) of 2010 includes provisions that could lead to new and improved treatments, cures and cost savings for patients. All of these changes, however, will impact the biotechnology industry and the future of patient access to needed medicines. In an expert panel at the 2013 BIO International Convention moderated by BioCentury’s Steve Usdin, multiple stakeholders addressed key elements of the ACA focused on both the value the ACA Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Show Me the Money: Reimbursement in an ACA World

BIO CEO 2013

A panel at the BIO CEO & Investor Conference focused on reimbursement discussed value from a variety of perspectives and agreed that the landscape is shifting dramatically. The reimbursement roundtable featured payors, providers, and other stakeholders discussing Affordable Care Act (ACA) implementation and the wider reimbursement landscape. With many key provisions of the ACA slated to take effect in 2013 and beyond, the industry is facing sweeping changes to the managed care and reimbursement road map. Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Biosimilars Ahead, Proceed with Caution

Richard Dolinar

By Richard M. Dolinar, M.D., Chairman, Alliance for Safe Biologic Medicines In today’s budget-constrained world, the goal for health care is not only to save lives but also to save money. On Friday, May 11, the Food and Drug Administration (FDA) will hold a one-day public hearing on important medicines, known as biosimilars, that are under FDA consideration to come to the United States (U.S.) and offer the opportunity to help achieve the second prong Read More >

Health  |  1 Comment  |  Email This Post
Tags: , , , , , , , , ,